The anti-deamidated gliadin peptide (DGP) IgA test detects the presence of IgA antibodies against deamidated gliadin peptides, which are associated with celiac disease. Celiac disease is an autoimmune disorder triggered by gluten ingestion, leading to intestinal damage. The anti-DGP IgA test helps diagnose celiac disease, especially in individuals with selective IgA deficiency. Elevated levels of anti-DGP IgA antibodies indicate an immune response to gluten, supporting the diagnosis of celiac disease. This test is used alongside other serological tests, such as tTG-IgA and EMA-IgA, to confirm the diagnosis and monitor adherence to a gluten-free diet.

The anti-deamidated gliadin peptide (DGP) IgG test detects the presence of IgG antibodies against deamidated gliadin peptides. This test is particularly useful for diagnosing celiac disease in individuals with IgA deficiency or inconclusive IgA-based test results. Elevated levels of anti-DGP IgG antibodies indicate an immune response to gluten, which supports the diagnosis of celiac disease. This test complements other serological tests like tTG-IgA and EMA-IgA to provide a comprehensive assessment for celiac disease. Monitoring these antibody levels can help evaluate the effectiveness of a gluten-free diet in patients with celiac disease.

This test measures the level of 1,5-Anhydroglucitol (1,5-AG) in the blood, which is used as an indicator of short-term glycemic control in diabetic patients. 1,5-AG levels decrease with hyperglycemia, as glucose competes with it for reabsorption in the kidneys. Hence, lower 1,5-AG levels indicate recent high blood sugar spikes. The test is particularly useful in detecting postprandial hyperglycemia and monitoring glucose control over the past 1 to 2 weeks. It complements other tests like HbA1c by providing additional insight into short-term glucose fluctuations.